ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA Article

Lee, Eudocia Q, Zhang, Peixin, Wen, Patrick Y et al. (2015). ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA . NEURO-ONCOLOGY, 17(suppl_5), v6-v6. 10.1093/neuonc/nov206.22

cited authors

  • Lee, Eudocia Q; Zhang, Peixin; Wen, Patrick Y; Gerstner, Elizabeth R; Reardon, David A; Aldape, Ken; de Groot, John F; Choe, Kevin S; Raizer, Jeffrey J; Kim, Lyndon J; Chmura, Steven J; Robins, H Ian; Connelly, Jennifer; Battiste, James; Villano, John; Wagle, Naveed; Merrell, Ryan T; Wendland, Merideth; Mehta, Minesh P

authors

publication date

  • November 1, 2015

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • v6

end page

  • v6

volume

  • 17

issue

  • suppl_5